Daniel Llwyd Hughes

Mr. Daniel Llwyd Hughes

Department of Oncology, University of Oxford
+1
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2021 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
DHDaniel Llwyd Hughes
Daniel Llwyd Hughes
AHA Hughes
A Hughes
PWP B White
P B White
MSM A Silva
M A Silva
Acute pancreatitis in pregnancy is uncommon, with an estimated incidence rate of between 1 in 1000 and 1 in 10 000 pregnancies 1, 2. One aspect that remains unclear is the impact of acute pancreatitis in pregnancy on maternal and fetal outcomes. Historical case series reported very poor outcomes, with maternal mortality rates of 20 per cent and fetal loss of 50 per cent 3, 4. However, these studies are of an era that is not representative of current clinical practice. There is a clear need to define recent outcomes of acute pancreatitis in pregnancy to create risk stratification criteria with which to identify patients most at risk of adverse outcomes. This meta-analysis aimed to quantify maternal and fetal outcomes in acute pancreatitis in pregnancy.

6 May 2019 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
DHDaniel Llwyd Hughes
Daniel Llwyd Hughes
IHIoan Hughes
Ioan Hughes
AKAchal Khanna
Achal Khanna

1 December 2020 in International Journal of Surgery
Verified
Journal Article
Closed access
DHDaniel Llwyd Hughes
Daniel Llwyd Hughes
GMGareth Morris-Stiff
Gareth Morris-Stiff
/Objectives: A paradigm shift has been observed in the management of mild gallstone pancreatitis; current guidelines advocate definitive cholecystectomy on the index admission. Despite the abundance of published guidelines, uncertainty remains with regard to the timing of cholecystectomy in moderate and severe acute pancreatitis (MAP/SAP), and no definitive consensus has been declared. This systematic review aimed to evaluate the published guidelines and subsequent evidence quoted in order to determine the optimal timing for cholecystectomy in this high-risk patient cohort. A systematic review of published literature was performed using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and AMSTAR (Assessing the methodological quality of systematic reviews) guidelines, and included a search of three online electronic databases. Eleven guidelines were included. Only 4 (36%) of guidelines specified an actual time frame for surgical intervention. Delaying surgery for a minimum of 6 weeks was advocated by all 4 guidelines. All recommendations were based upon weak or very low-quality evidence. Higher mortality rates were observed when patients underwent early cholecystectomy for SAP (1.3-44%) when compared to patients who underwent delayed surgery (0-11%). Marked variation was observed amongst the published guidelines on the definitive management of MAP and SAP and disparity remains on the timing of cholecystectomy. A minority of the guidelines proposed a specific time period for when cholecystectomy should be performed, and whilst based on low quality evidence, delaying surgery (for 6 weeks) is associated with a reduction in morbidity and mortality rates and should be advocated in MAP/SAP until level 1 evidence becomes available.

5 July 2024 in Science Advances
Verified
Journal Article
Open access
DHDaniel Llwyd Hughes
Daniel Llwyd Hughes
AEAlice Evans
Alice Evans
SGSimei Go
Simei Go
MEMichael Eyres
Michael Eyres
LPLiuliu Pan
Liuliu Pan
EOEric O'Neill
Eric O'Neill
Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer, a disease with dismal overall survival. Advances in treatment are hindered by a lack of preclinical models. Here, we show how a personalized organotypic “avatar” created from resected tissue allows spatial and temporal reporting on a complete in situ tumor microenvironment and mirrors clinical responses. Our perfusion culture method extends tumor slice viability, maintaining stable tumor content, metabolism, stromal composition, and immune cell populations for 12 days. Using multiplexed immunofluorescence and spatial transcriptomics, we identify immune neighborhoods and potential for immunotherapy. We used avatars to assess the impact of a preclinically validated metabolic therapy and show recovery of stromal and immune phenotypes and tumor redifferentiation. To determine clinical relevance, we monitored avatar response to gemcitabine treatment and identify a patient avatar-predictable response from clinical follow-up. Thus, avatars provide valuable information for syngeneic testing of therapeutics and a truly personalized therapeutic assessment platform for patients.

1 August 2019 in Health Technology Assessment
Verified
Journal Article
Closed access
BRBarnaby C Reeves
Barnaby C Reeves
LRLeila Rooshenas
Leila Rooshenas
RMRhiannon C Macefield
Rhiannon C Macefield
MWMark Woodward
Mark Woodward
NWNicky J Welton
Nicky J Welton
JBJane M Blazeby
Jane M Blazeby
Background: Surgical site infection (SSI) affects up to 20% of people with a primary closed wound after surgery. Wound dressings may reduce SSI. Objective: To assess the feasibility of a multicentre randomised controlled trial (RCT) to evaluate the effectiveness and cost-effectiveness of dressing types or no dressing to reduce SSI in primary surgical wounds. Design: Phase A – semistructured interviews, outcome measure development, practice survey, literature reviews and value-of-information analysis. Phase B – pilot RCT with qualitative research and questionnaire validation. Patients and the public were involved. Setting: Usual NHS care. Participants: Patients undergoing elective/non-elective abdominal surgery, including caesarean section. Interventions: Phase A – none. Phase B – simple dressing, glue-as-a-dressing (tissue adhesive) or ‘no dressing’. Main outcome measures: Phase A – pilot RCT design; SSI, patient experience and wound management questionnaires; dressing practices; and value-of-information of a RCT. Phase B – participants screened, proportions consented/randomised; acceptability of interventions; adherence; retention; validity and reliability of SSI measure; and cost drivers. Data sources: Phase A – interviews with patients and health-care professionals (HCPs), narrative data from published RCTs and data about dressing practices. Phase B – participants and HCPs in five hospitals. Results: Phase A – we interviewed 102 participants. HCPs interpreted ‘dressing’ variably and reported using available products. HCPs suggested practical/clinical reasons for dressing use, acknowledged the weak evidence base and felt that a RCT including a ‘no dressing’ group was acceptable. A survey showed that 68% of 1769 wounds (727 participants) had simple dressings and 27% had glue-as-a-dressing. Dressings were used similarly in elective and non-elective surgery. The SSI questionnaire was developed from a content analysis of existing SSI tools and interviews, yielding 19 domains and 16 items. A main RCT would be valuable to the NHS at a willingness to pay of £20,000 per quality-adjusted life-year. Phase B – from 4 March 2016 to 30 November 2016, we approached 862 patients for the pilot RCT; 81.1% were eligible, 59.4% consented and 394 were randomised (simple, n = 133; glue, n = 129; no dressing, n = 132); non-adherence was 3 out of 133, 8 out of 129 and 20 out of 132, respectively. SSI occurred in 51 out of 281 participants. We interviewed 55 participants. All dressing strategies were acceptable to stakeholders, with no indication that adherence was problematic. Adherence aids and patients’ understanding of their allocated dressing appeared to be key. The SSI questionnaire response rate overall was 67.2%. Items in the SSI questionnaire fitted a single scale, which had good reliability (test–retest and Cronbach’s alpha of > 0.7) and diagnostic accuracy (c-statistic = 0.906). The key cost drivers were hospital appointments, dressings and redressings, use of new medicines and primary care appointments. Limitations: Multiple activities, often in parallel, were challenging to co-ordinate. An amendment took 4 months, restricting recruitment to the pilot RCT. Only 67% of participants completed the SSI questionnaire. We could not implement photography in theatres. Conclusions: A main RCT of dressing strategies is feasible and would be valuable to the NHS. The SSI questionnaire is sufficiently accurate to be used as the primary outcome. A main trial with three groups (as in the pilot) would be valuable to the NHS, using a primary outcome of SSI at discharge and patient-reported SSI symptoms at 4–8 weeks. Trial registration: Phase A – Current Controlled Trials ISRCTN06792113; Phase B – Current Controlled Trials ISRCTN49328913. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 39. See the NIHR Journals Library website for further project information. Funding was also provided by the Medical Research Council ConDuCT-II Hub (reference number MR/K025643/1).

2 February 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
DHDaniel Llwyd Hughes
Daniel Llwyd Hughes
IHIoan Hughes
Ioan Hughes
MSMichael A. Silva
Michael A. Silva